The 36-month beta value for MRSN is also noteworthy at 1.41. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for MRSN is 90.06M, and at present, short sellers hold a 10.96% of that float. The average trading volume of MRSN on November 13, 2024 was 1.04M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
MRSN) stock’s latest price update
Mersana Therapeutics Inc (NASDAQ: MRSN) has experienced a decline in its stock price by -13.04 compared to its previous closing price of 2.53. However, the company has seen a gain of 9.45% in its stock price over the last five trading days. globenewswire.com reported 2024-11-06 that CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) — Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the third quarter ended September 30, 2024 on Wednesday, November 13, 2024. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning.
MRSN’s Market Performance
Mersana Therapeutics Inc (MRSN) has experienced a 9.45% rise in stock performance for the past week, with a 6.80% rise in the past month, and a 78.86% rise in the past quarter. The volatility ratio for the week is 12.48%, and the volatility levels for the past 30 days are at 8.01% for MRSN. The simple moving average for the past 20 days is 4.86% for MRSN’s stock, with a -19.59% simple moving average for the past 200 days.
Analysts’ Opinion of MRSN
Many brokerage firms have already submitted their reports for MRSN stocks, with JP Morgan repeating the rating for MRSN by listing it as a “Neutral.” The predicted price for MRSN in the upcoming period, according to JP Morgan is $5 based on the research report published on March 19, 2024 of the current year 2024.
Wedbush, on the other hand, stated in their research note that they expect to see MRSN reach a price target of $7, previously predicting the price at $2. The rating they have provided for MRSN stocks is “Outperform” according to the report published on February 29th, 2024.
Guggenheim gave a rating of “Buy” to MRSN, setting the target price at $7 in the report published on February 29th of the current year.
MRSN Trading at 11.68% from the 50-Day Moving Average
After a stumble in the market that brought MRSN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -64.97% of loss for the given period.
Volatility was left at 8.01%, however, over the last 30 days, the volatility rate increased by 12.48%, as shares surge +3.29% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +51.72% upper at present.
During the last 5 trading sessions, MRSN rose by +9.45%, which changed the moving average for the period of 200-days by -36.78% in comparison to the 20-day moving average, which settled at $2.10. In addition, Mersana Therapeutics Inc saw -5.17% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MRSN starting from Bala Mohan, who sale 1,884 shares at the price of $1.90 back on Oct 28 ’24. After this action, Bala Mohan now owns 54,731 shares of Mersana Therapeutics Inc, valued at $3,580 using the latest closing price.
Bala, Mohan, the Officer of Mersana Therapeutics Inc, proposed sale 1,884 shares at $2.04 during a trade that took place back on Oct 28 ’24, which means that Bala, Mohan is holding shares at $3,843 based on the most recent closing price.
Stock Fundamentals for MRSN
Current profitability levels for the company are sitting at:
- -3.6 for the present operating margin
- 0.94 for the gross margin
The net margin for Mersana Therapeutics Inc stands at -3.5. The total capital return value is set at -0.92. Equity return is now at value -213.33, with -42.75 for asset returns.
Based on Mersana Therapeutics Inc (MRSN), the company’s capital structure generated 0.78 points at debt to capital in total, while cash flow to debt ratio is standing at -4.64. The debt to equity ratio resting at 3.45. The interest coverage ratio of the stock is -26.63.
Currently, EBITDA for the company is -166.08 million with net debt to EBITDA at 0.27. When we switch over and look at the enterprise to sales, we see a ratio of 8.12. The receivables turnover for the company is 19.07for trailing twelve months and the total asset turnover is 0.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.72.
Conclusion
In summary, Mersana Therapeutics Inc (MRSN) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
